This is a working overview of GIP receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-21. Anything still debated is marked as such rather than presented as settled.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
| Property | Value | Notes |
|---|---|---|
| Appearance | white to off-white powder | Lyophilised solid form |
| Solubility | pH dependent; low near pI | Minimum close to pH 5.4 |
| Storage temperature | -20 C solid; 2-8 C solution | Protect from light |
| Isoelectric point | approx. pH 5.4 | Controls solubility minimum |
| Common analytical method | RP-HPLC with mass detection | Purity and identity checks |
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
=== 1910s === In 1912, the Institute of Biomedical Science was founded in the United Kingdom. The institute is still standing today and still regularly publishes works in the major breakthroughs in disease treatments and other breakthroughs in the field 117 years later. The IBMS today represents approximately 20,000 members employed mainly in National Health Service and private laboratories.
=== Classification === Historical classification systems were based on clinical factors. Until the early 1970s, the idea of a single amyloid substance predominated. Various descriptive classification systems were proposed based on the organ distribution of amyloid deposits and clinical findings. Most classification systems included primary (i.e., idiopathic) amyloidosis, in which no associated clinical condition was identified, and secondary amyloidosis (i.e., secondary to chronic inflammatory conditions). Some classification systems included myeloma-associated, familial, and localized amyloidosis. The modern era of amyloidosis classification began in the late 1960s with the development of methods to make amyloid fibrils soluble. These methods permitted scientists to study the chemical properties of amyloids. Descriptive terms such as primary amyloidosis, secondary amyloidosis, and others (e.g., senile amyloidosis), which are not based on cause, provide little useful information and are no longer recommended. The modern classification of amyloid disease tends to use an abbreviation of the protein that makes the majority of deposits, prefixed with the letter A. For example, amyloidosis caused by transthyretin is termed "ATTR". Deposition patterns vary between people but are almost always composed of just one amyloidogenic protein. Deposition can be systemic (affecting many different organ systems) or organ-specific. Many amyloidoses are inherited, due to mutations in the precursor protein.
Oxycodone, like other opioid analgesics, tends to induce feelings of euphoria, relaxation, and reduced anxiety in those who are occasional users. The abuse of oxycodone, as well as related opioids more broadly, is not unique to the United States and it is a common drug of abuse globally.
== History == Polatuzumab vedotin was discovered by a team at Genentech led by Dan Eaton, Fred de Sauvage, and Andy Polson, who had been trying to develop ADCs for solid tumors without success, and in 2002 turned to blood cancers. In June 2019, polatuzumab vedotin was approved in the United States in combination with the chemotherapy bendamustine and a rituximab product, to treat adults with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies. Polatuzumab vedotin is a novel antibody-drug conjugate, and DLBCL is the most common type of non-Hodgkin lymphoma. The US Food and Drug Administration (FDA) granted accelerated approval to polatuzumab vedotin used in combination with the chemotherapy bendamustine and a rituximab product. The FDA approved polatuzumab vedotin based primarily on evidence from one clinical trial (NCT02257567) that was conducted in the United States, Canada, Europe, and Asia. Participants in the trial had lymphoma that came back or did not improve after prior treatment. The FDA granted the application of polatuzumab vedotin breakthrough therapy, priority review, and orphan drug designations. The FDA granted the approval of Polivy to Genentech. Polatuzumab vedotin was approved for medical use in the European Union in January 2020, as a second-line treatment. The European Medicines Agency (EMA) designated polatuzumab vedotin an orphan medicine in April 2018.
Notably, fecal ssRNA was identified as a natural Piezo1 ligand, and ssRNA-stimulated 5-HT synthesis from the gut was evoked in a MyD88/TRIF-independent manner. Colonic infusion of RNase A suppressed gut motility and increased bone mass. These findings suggest gut ssRNA as a master determinant of systemic 5-HT levels, indicating the ssRNA-Piezo1 axis as a potential prophylactic target for treatment of bone and gut disorders. Studies in 2008, 2010 and 2019 have opened the potential for serotonin research to treat bone mass disorders.
Sources: en.wikipedia.org
=== Surgical debridement === Surgical or "sharp" debridement and laser debridement under anesthesia are the fastest methods of debridement. They are very selective, meaning that the person performing the debridement has nearly complete control over which tissue is removed and which is left behind. Surgical debridement can be performed in the operating room or bedside, depending on the extent of the necrotic material and a patient's ability to tolerate the procedure. The surgeon will typically debride tissue back to viability, as determined by tissue appearance and the presence of blood flow in healthy tissue.
Before beginning the process of restoration of a herbarium sheet, best practices suggest that the original mounted specimen be photographed for reference to ensure a new sheet is as close to the original as possible. The original mounting sheet can be dried and flattened in the same manner as the plant to serve as a reference for positioning the specimen on a new sheet. Additionally, any labels or supplement information accompanying the plant should be placed in the same place.
==== Tests for pigments ==== In October 1978 a team of scientists affiliated with STURP took 32 samples from the surface of the Shroud, using adhesive tape. Of those samples, 18 were taken from areas of the Shroud that showed a body or blood image, while 14 were taken from non-image areas. The chemical microscopist Walter McCrone, a leading expert in the forensic authentication of historical documents and works of art, examined the tapes using polarized light microscopy and other physical and chemical techniques. McCrone concluded that the Shroud's body image had been painted with a dilute pigment of red ochre (a form of iron oxide) in a collagen tempera (i.e., gelatin) medium, using a technique similar to the grisaille employed in the 14th century by Simone Martini and other European artists. McCrone also found that the "bloodstains" in the image had been highlighted with vermilion (a bright red pigment made from mercury sulfide), also in a collagen tempera medium. McCrone reported that no actual blood was present in the samples taken from the Shroud. Other members of STURP rejected McCrone's conclusions and concluded, based on their own examination of the Shroud and the tape samples, that the image on the Shroud could not be explained by the presence of pigments. Mark Anderson, who was working for McCrone, analyzed the Shroud samples. In his book, chemist Raymond Rogers states that Anderson, who was McCrone's Raman microscopy expert, concluded that the samples acted as organic material when he subjected them to the laser.
== Clinical presentation == Patients with hemoglobin H disease present with chronic hemolytic anemia that ranges in severity from mild to moderate disease. Anemia is the most common presenting symptom of patients with HbH disease. Other common clinical features include jaundice, splenomegaly, hepatomegaly, and gallstones. All of these symptoms are related to the destruction of the red blood cells in the spleen and the associated increased hemoglobin metabolism. Patients with non-deletional HbH disease are more likely to be symptomatic and have severe disease presentation when compared to individuals with deletional HbH disease. Disease presentation varies from asymptomatic individuals to neonatal growth retardation and death in the most severe cases. Death in the neonatal period occurs due to the severe anemia resulting in hydrops fetalis. Patients most often present initially due to hemolytic episodes that occur during times of infection or inflammation. During these episodes, patients may develop hemolytic crisis, in which there is a rapid drop in the hemoglobin due to increased red blood cell destruction.
The two main types of dialysis, hemodialysis and peritoneal dialysis, remove wastes and excess water from the blood in different ways. Hemodialysis removes wastes and water by circulating blood outside the body through an external filter, called a dialyzer, that contains a semipermeable membrane. The blood flows in one direction and the dialysate flows in the opposite. The counter-current flow of the blood and dialysate maximizes the concentration gradient of solutes between the blood and dialysate, which helps to remove more urea and creatinine from the blood. The concentrations of solutes normally found in the urine (for example potassium, phosphorus and urea) are undesirably high in the blood, but low or absent in the dialysis solution, and constant replacement of the dialysate ensures that the concentration of undesired solutes is kept low on this side of the membrane. The dialysis solution has levels of minerals like potassium and calcium that are similar to their natural concentration in healthy blood. For another solute, bicarbonate, dialysis solution level is set at a slightly higher level than in normal blood, to encourage the diffusion of bicarbonate into the blood, to act as a pH buffer to neutralize the metabolic acidosis that is often present in these patients. The levels of the components of dialysate are typically prescribed by a nephrologist according to the needs of the individual patient. In peritoneal dialysis, wastes and water are removed from the blood inside the body using the peritoneum as a natural semipermeable membrane.
Sources: en.wikipedia.org
Another major effort against the Huks was Operation "Knockout" of the Panay Task Force (composed of the 15th BCT, some elements of the 9th BCT and the PC commands of Iloilo, Capiz, and Antique) under the command of Colonel Alfredo M. Santos. The Operation conducted a surprise attack on Guillermo Capadocia, commander of the Huk Regional Command in the Visayas, erstwhile Secretary General and one of the founders of the PKP. Santos' masterstroke was the enlistment of Pedro Valentin, a local mountain leader who knew the people and the terrain like the back of his hand. Capadocia died on Panay, of battle wounds, on September 20, 1952. In 1954, Lieutenant Colonel Laureño Maraña, the former head of Force X of the 16th PC Company, assumed command of the 7th BCT, which had become one of the most mobile striking forces of the Philippine ground forces against the Huks, from Valeriano who was now a colonel. Force X employed psychological warfare through combat intelligence and infiltration that relied on secrecy in planning, training, and execution of attack. The lessons learned from Force X and Nenita were combined in the 7th BCT.
A wide range of reproductive strategies have been noted in ant species. Females of many species are known to be capable of reproducing asexually through thelytokous parthenogenesis. Secretions from the male accessory glands in some species can plug the female genital opening and prevent females from re-mating. Most ant species have a system in which only the queen and breeding females have the ability to mate. Contrary to popular belief, some ant nests have multiple queens, while others may exist without queens. Workers with the ability to reproduce are called "gamergates" and colonies that lack queens are then called gamergate colonies; colonies with queens are said to be queen-right. In the ant Cataglyphis hispanica, workers are produced by hybridization of two distinct lineages while the male and female reproductives are produced through (asexual) parthenogenesis. The production of hybrid workers with the existence of non-hybrid queens and males has been termed as "social hybridogenesis". This has been noted in the genera Messor, Pogonomyrmex, Cataglyphis and Solenopsis. The use of sperm of another species by females has been termed as sperm parasitism. A more complex situation was discovered in 2025 where Messor ibericus queens were shown to lay some eggs that developed into workers which match genetically with a different species of ant, Messor structor. Although the two species overlap in some parts of their range, the colonies studied were on the island of Sicily where M. ibericus alone is found. Queen M. ibericus in this region were able to produce M.
== Current status == PeptideAtlas is still maintained and developed at the Institute for Systems Biology in the research lab of Robert Moritz, led by Eric Deutsch, and with significant efforts by Zhi Sun and Dave Campbell.
== Invertebrates == In some invertebrates, such as Porifera, Cnidaria, Ctenophora, and some triploblasts (namely the acoelomates), the term "mesenchyme" refers to a more-or-less solid but loosely organized tissue that consists of a gel matrix (the mesoglea) with various cellular and fibrous inclusions, located between the epidermis and the gastrodermis (non-triploblast animals usually are considered to lack "connective" tissue). In some cases, the mesoglea is noncellular.
Sources: en.wikipedia.org
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.
Mass spectrometry, usually electrospray ionisation coupled to liquid chromatography, gives an observed mass for comparison with the theoretical value. Peptide mapping after digestion provides complementary sequence-level confirmation.
Short exposure during weighing and handling is generally tolerated, but prolonged storage above refrigerated conditions raises the risk of deamidation, oxidation, and aggregation. The rate depends on pH, buffer composition, and concentration.
Peptide mapping with tandem mass spectrometry is the standard approach. The peptide is digested with an enzyme such as trypsin, and the resulting fragments are matched against the expected sequence.